Positions 101–125 of 130.
The title is the argument: dual agonist is doing more work than we give it credit for. Here is the rest of it. The distribution matters more than the mean. In the trial…
anyone else notice GIP kicking in around week 81, logged the same way every week so the comparison is at least internally fair. Sulphur burps for the first eight days…
small win: dual agonist stopped being a problem at week 50, and the part I actually want to talk about is at the bottom. Week 7 was the first time the scale moved after…
can we stop arguing about Zepbound until somebody posts a number. I am not trying to be the "source?" guy. I would just like a source. Sulphur burps for the first eight…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netPosting this as a discussion rather than a claim: the GIP advice in here is 2 years out of date. To save the first four comments: 2 years. The step schedule question,…
my ApoB moved and I cannot work out whether SURPASS is why. Change my mind, genuinely — I have no stake in being right about this. Switching from semaglutide, since…
the SURPASS rule is doing its job and people should stop complaining, and here is what changes in practice if it goes ahead. SURMOUNT-1 ran 72 weeks with the top arm…
Posting this because the title is the whole finding — 22th independent test on WXT — 99.2% on a claimed 98.5%, and the trend is the interesting part — and a number…
Posting this as a discussion rather than a claim: my fasting insulin moved and I cannot work out whether Zepbound is why. Vials and pens carry the same molecule; what…
am I the only one who found Zepbound harder than the injections, and I want the answer with the reasoning attached rather than just the conclusion. The four-week…
Check-in as promised in the title: is it normal to get muscle cramps at week 54. Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped…
Filing this under things worth writing down: QST vs WWB on the same compound, same month — both cleared 99.0%. Figures up front so nobody has to dig: 99.0%. Went 10 to…
the tirzepatide rule is doing its job and people should stop complaining, and it will stay as it is unless somebody makes the case to change it. The four-week interval…
tirzepatide: the version I wish someone had shown me in week 1. This is a description of what happened to me and not a plan for anybody else. 20kg over 46 weeks, never…
am I the only one who found tirzepatide harder than the injections. I am not trying to be the "source?" guy. I would just like a source. The four-week interval in the…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsNumbers in the title, numbers in the post. split one vial across Medutest and Janoshik — 98.3% and 98.7%. Since the title puts numbers in the shop window: 98.3% and…
genuine question about SURMOUNT that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete. Switching from…
unpopular opinion: most of what gets said here about GIP is guesswork. Making the case below, and I expect to lose some of it in the comments. SURMOUNT-1 ran 72 weeks…
Check-in as promised in the title: week 46 check-in — 21kg down, early fullness manageable, one thing confusing me. The relevant figures are week 46 and 21kg, and they…
Something I keep coming back to: the Mounjaro thing finally clicked for me and I want to write it down. Week 47 was the first time the scale moved after a five-week…
Asking properly rather than in a comment on somebody else’s thread: 15mg — what am I missing here. Numbers, in the order they matter: 15mg. Appetite effect for me is…
Six-word version is the title — week 16 check-in — 5kg down, reflux manageable, one thing confusing me — and the rest is context. The relevant figures are week 16 and…
Trying to get a straight answer on this: can we stop arguing about dual agonist until somebody posts a number. Vials and pens carry the same molecule; what differs is…
tirzepatide — what am I missing here. If this has been answered properly somewhere, link me and I will delete. Went 10 to 12.5 on the calendar and had the worst…
Asking properly rather than in a comment on somebody else’s thread: how do you actually verify GIP. Vials and pens carry the same molecule; what differs is fill volume,…
Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference